The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Regenerative Pharmacology

This group focuses on fostering translational pharmacological projects, all the way from an initial discovery in experimental models to clinical studies.

The process of drug development starting with a molecule, cell culturing and mouse models to study the brain, ending with a couple of pills in an open hand. Illustration.
Drug development requires a translational approach, from molecular investigations in cell cultures and animal models of neurodegenerative disorders to clinical trials involving patients. Illustration created with Biorender.

This special interest group gathers researchers using and developing pharmacological tools to understand and treat neurodegenerative diseases and neurodegeneration following acute conditions like ischemic stroke and traumatic brain injuries. We combine pharmacological studies with investigations into the mechanisms of action of different treatments.

In alignment with MultiPark's strategic goals

  • To span from internationally leading pre-clinical research to translational and multidisciplinary clinical research across the spectrum of the main neurodegenerative diseases.
  • To create new therapeutic approaches for prevention, disease modification and management of unmet medical needs.

Overarching goals

  • Develop pharmacological treatment principles for neurodegenerative diseases and related brain disorders.
  • Foster a translational and integrative approach that can bridge experimental and clinical pharmacology.
  • Exploit pharmacological tools to advance mechanism-oriented research.

Planned activities

  • Biannual meetings to discuss common interests and initiatives.
  • More targeted meetings on demand to accelerate the development of strategically important projects.
  • Outreaching seminars and workshops, possibly involving MultiPark-supported infrastructures or other special interest groups. (topic example: drug candidates identification, validation, and testing in animal models).
  • Joint activities with the Multipark innovation group (e.g. seminars about protection of intellectual properties and developing discoveries).